Zobrazeno 1 - 10
of 1 048
pro vyhledávání: '"Recurrent Hepatocellular Carcinoma"'
Autor:
Jeffrey To, Soumita Ghosh, Xun Zhao, Elisa Pasini, Sandra Fischer, Gonzalo Sapisochin, Anand Ghanekar, Elmar Jaeckel, Mamatha Bhat
Publikováno v:
Human Genomics, Vol 18, Iss 1, Pp 1-12 (2024)
Abstract Background Liver transplantation (LT) is offered as a cure for Hepatocellular carcinoma (HCC), however 15–20% develop recurrence post-transplant which tends to be aggressive. In this study, we examined the transcriptome profiles of patient
Externí odkaz:
https://doaj.org/article/6bd3bd44dd4b43f0bb30d758de803db7
Radiofrequency ablation for pediatric recurrent hepatocellular carcinoma: a single-center experience
Publikováno v:
BMC Medical Imaging, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Purpose To summarize our single-center experience with percutaneous ultrasound (US)-guided radiofrequency ablation (RFA) for pediatric recurrent hepatocellular carcinoma (RHCC). Methods From September 2007 to September 2021, patients under 1
Externí odkaz:
https://doaj.org/article/5fd25fb0a50c41dfb419e42762a8f671
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThis meta-analysis was conducted to assess the survival benefits of repeat hepatectomy (RH) and thermal ablation therapy (TAT) in managing recurrent hepatocellular carcinoma (HCC).MethodsA comprehensive search was conducted in the PubMed, S
Externí odkaz:
https://doaj.org/article/d70fdb1c21c7430aadb3a88a261778b5
Autor:
Zhenyu Wen, Junxiao Wang, Bo Tu, Yane Liu, Yuqing Yang, Li Hou, Xiang Yang, Xiaoyan Liu, Hui Xie
Publikováno v:
Cancer Medicine, Vol 12, Iss 20, Pp 20311-20320 (2023)
Abstract Objective The effectiveness and security of radiofrequency ablation (RFA) in combination with toripalimab (anti‐PD‐1) for the treatment of recurrent hepatocellular carcinoma (HCC) was studied in this article. Methods Total of 40 patients
Externí odkaz:
https://doaj.org/article/ebf45b46a35b48c7bd644f29d77efbc3
Autor:
I. A. Dzhanyan, M. S. Novruzbekov, O. D. Olisov, D. I. Yudin, V. S. Rudakov, E. Yu. Antonova, I. V. Savchenko, I. V. Pogrebnyakov, V. V. Breder, M. Yu. Pitkevich
Publikováno v:
Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье, Vol 13, Iss 4, Pp 162-168 (2023)
Hepatocellular carcinoma (HCC) is the third cause of cancer-related mortality worldwide, accounting for more than 800,000 deaths annually. Surgical removal of the neoplasm remains the most effective treatment option. Partial liver resection is an ade
Externí odkaz:
https://doaj.org/article/02e2772863cf41b8b0e78f9f587502c8
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 10, Pp 893-908 (2023)
Sizhe Liu, Le Kang, Yagang Song, Mingsan Miao School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, People’s Republic of ChinaCorrespondence: Mingsan Miao, School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou,
Externí odkaz:
https://doaj.org/article/51136a3fc1d848d9a68655f415b02c1c
Autor:
Yang Zhao, Tongwang Yang, Yabo Ouyang, Wei Rao, Kai Liu, Jiasheng Zheng, Fudong Lv, Ying Shi, Feng Wang, Dongjie Liu, Luxin Qiao, Zhenying Xia, Yushi Zhang, Dexi Chen, Wenjing Wang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundRadiofrequency ablation (RFA) is the primary curative treatment for hepatocellular carcinoma (HCC) patients who are not eligible for surgery. However, the effects of RFA on the global tumor immune response remain unclear.MethodIn this study
Externí odkaz:
https://doaj.org/article/6eaf9cff89c54b47beba70bf1b4970cc
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 9213-9227 (2023)
Abstract Background The surgical indications and therapeutic strategies for early‐stage multifocal and recurrent hepatocellular carcinoma (rHCC) remain controversial. This study compared the long‐term outcome of patients with recurrent and multif
Externí odkaz:
https://doaj.org/article/3c2ac4288b0f47b68bf79ac2d4b9c698
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
PurposeTo explore the safety and efficacy of lenvatinib in combination with trans-arterial chemoembolization (TACE) and programmed death receptor 1 (PD-1) antibody in the treatment of unresectable recurrent hepatocellular carcinoma (urHCC).Patients a
Externí odkaz:
https://doaj.org/article/af40680f9b6f4d359775b289603397c8
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
BackgroundPostoperative recurrence of hepatocellular carcinoma (HCC) is associated with low survival rates. While HCC treatment options have expanded substantially, they are accompanied by several challenges. This study assessed the outcomes of repea
Externí odkaz:
https://doaj.org/article/c9cb756cee5f4be780ba291574b5f49f